Evaluating congestion markers in patients with acute heart failure
Acute Heart Failure With Reduced Ejection Fraction - COngestion Discharge Evaluation: Evaluation de la Congestion à la Sortie d'Hospitalisation Pour Insuffisance Cardiaque aiguë à Fraction d'éjection altérée ou modérément altérée
This study is trying to find out if certain tests done on patients with acute heart failure before they leave the hospital can help predict their risk of dying or being readmitted within three months.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Locations | 1 site (Vandœuvre-lès-Nancy) |
| Trial ID | NCT04343443 on ClinicalTrials.gov |
What this trial studies
The AHF-CODE study is a prospective, non-randomized study focusing on patients hospitalized for acute heart failure with reduced ejection fraction. It aims to identify clinical, biological, and ultrasound markers of congestion at the time of discharge that may predict the risk of death or rehospitalization within three months. The study involves various assessments, including Doppler ultrasounds and blood sample analysis, to gather comprehensive data on the patients' conditions. This approach seeks to enhance understanding of heart failure management and improve patient outcomes post-discharge.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are hospitalized for acute heart failure with reduced ejection fraction.
Not a fit: Patients with severe comorbidities, those on dialysis, or with significant pulmonary issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better risk stratification and management strategies for patients with acute heart failure.
How similar studies have performed: Other studies have shown promise in identifying congestion markers in heart failure, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients hospitalised for acute heart failure. * Patients with reduced ejection fraction (Ejection Fraction \<40%) or (40% ≤ Ejection Fraction \< 50) * Patients considered clinically discharging from hospitalisation for acute heart failure. * Age ≥18 years * Patients having received complete information regarding the study design and having signed their informed consent form. * Patient affiliated to or beneficiary of a social security scheme. Exclusion Criteria: * Comorbidity for which the life expectancy is ≤ 3 months * Dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular filtration rate \<15 ml/min/m2 at inclusion. * History of lobectomy or pneumonectomy lung surgery * Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc. * Pregnant woman, parturient or nursing mother * Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice) Adult person who is unable to give consent * Person deprived of liberty by a judicial or administrative decision, * Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code.
Where this trial is running
Vandœuvre-lès-Nancy
- CHRU de Nancy — Vandœuvre-lès-Nancy, France (Recruiting)
Study contacts
- Study coordinator: Nicolas GIRERD
- Email: n.girerd@chru-nancy.fr
- Phone: + 33 3 83 15 73 22
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.